Despite existing chemotherapy and surgical resection strategies, pancreatic cancer is one of the major causes of mortality in the United States with a 5-year mean survival of less than 5%. The activation of the uPAR-uPA system in the development of pancreatic ductal adenocarcinoma has been well established. In the present study, we used two pancreatic cancer cell lines, MIA PaCa-2 and PANC-1 to demonstrate the effects of uPAR and uPA down regulation. From the results, we observed that RNAi expressing plasmids efficiently down regulated mRNA and protein expression of uPAR and uPA. In vitro and in vivo angiogenic assays revealed a significant decrease in the angiogenic potential of MIA PaCa-2 and PANC-1 cells that were down regulated for both uPAR and uPA. From the angiogenesis antibody array analysis, we observed that the simultaneous down regulation of uPAR and uPA resulted in the down regulation of angiogenin and over expression of RANTES. Further, FACS analysis demonstrated that the simultaneous down regulation of uPAR and uPA caused the accumulation of cells in the subG 0/1 phase in both MIA PaCa-2 and PANC-1 cells. In addition, western blot analysis revealed that down regulation of uPAR and uPA caused the activation of caspase 8 and CAD, which is indicative of apoptosis, in vivo TUNEL assay confirmed these results. Finally, we observed the nuclear localization of uPA and that uPA interacts with the transcription factor Lhx-2. Taken together, the results of the present study demonstrate that the targeting of the uPAR-uPA system has therapeutic potential.
INTRODUCTION
Each year about 37,000 individuals in the United States are diagnosed with pancreatic cancer, and more than 30,000 die from the disease. Depending on the size of the tumor at the time of diagnosis, prognosis is generally poor with less than 5 percent still alive five years after diagnosis, and complete remission is extremely rare (1) . Treatment of pancreatic cancer depends on the stage of the cancer. Gemcitabine was approved by the FDA in 1998 after a clinical trial reported improvements in quality of life in patients with advanced pancreatic cancer; this marked the first FDA approval of a chemotherapy drug for a non-survival clinical trial endpoint (2) .
Patients diagnosed with pancreatic cancer typically have a poor prognosis partly because the cancer usually does not cause symptoms at earlier stages, which leads to locally advanced or metastatic disease by the time of diagnosis. Median survival is 3 to 6 months after diagnosis and as mentioned earlier, the five-year survival rate is less than 5 percent (3). Although it accounts for only 2.5 percent of new cases, pancreatic cancer is responsible for 6 percent of cancer deaths each year (4) . The survival rate (3) and high recurrence after surgery clearly demonstrate the need for novel therapies (5) .
Importance of the uPAR-uPA system in pancreatic cancers
Recent studies have suggested that the expression levels of uPA and fibroblastic uPAR are correlated with liver metastasis of human pancreatic cancer (6) , indicating the relevance of specifically targeting the uPAR-uPA system. Other studies have demonstrated similar results and have shown the importance of the uPAR-uPA system in pancreatic carcinoma cell migration (7) .
Invasion studies also suggest that uPAR is a potential target for therapy in patients with pancreatic cancer (1, (6) (7) (8) (9) (10) . In addition, studies have demonstrated the influence of the IGF (insulin-like growth factor) system on tumor progression from benign mucinous cystadenomas (BMC) to pancreatic ductal adenocarcinoma (PDAC) (11) . However, the uPAR-uPA system had a greater influence on survival of PDAC (11) , which highlights the importance of targeting the uPAR-uPA system.
uPAR-uPA associated complex
Malignant tumors have the capacity to degrade the extracellular matrix (ECM) by controlled proteolysis. One proteolytic system involved in these processes is the urokinase-type plasminogen activator (uPA) system, which consists of uPA, the uPA receptor (uPAR) and uPA inhibitors 1 and 2 (PAI-1 and PAI-2). A growing body of evidence suggests that the uPA system promotes tumor metastasis by several different mechanisms and not solely through the breakdown of the ECM (12) . Initially, uPAR was thought to function simply as a mechanism to concentrate the urokinase/plasmin system near the cell surface. However, extensive evidence has since shown that this glycolipid-anchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. One mechanism through which uPAR directs these actions is by complexing with other membrane proteins (e.g., integrins) for signal transduction.
There are three basic steps involved in invasion and intracellular signaling: (1) uPAR-uPA promotes extracellular proteolysis by regulating plasminogen activation, (2) uPAR-uPA regulates cell/ECM interactions as an adhesion receptor for vitronectin (Vn) and through its capacity to modulate integrin function, and (3) uPAR-uPA regulates cell migration as a signal transduction molecule and by its intrinsic chemotactic activity (13) .
Recent studies point to important structural features of uPAR-integrin interactions, suggesting uPAR is a cis-acting integrin ligand (14) . Although uPAR transcripts are induced by adhesion, rapid synthesis of the protein uses constitutive mRNA without a requirement for new transcription and is regulated by mammalian target of rapamycin, demonstrating new biologic roles for the signal-dependent translation pathway controlled by this intracellular kinase (15) .
Integrins are known to activate PI3K and MEK pathway, and higher activation of Akt is associated with increased phosphorylation of glycogen synthase kinase 3β (GSK3β), FKHR and mTOR (16) , indicating a possible feedback mechanism. Researchers have demonstrated that urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β (17) , which demonstrates its multifaceted role in signaling. In the present study, we further delineated the complex role of uPAR and its associated molecules in activating apoptosis in pancreatic cancer.
MATERIALS AND METHODS
Cell lines and culture conditions: MIA PaCa-2 and PANC-1 cells were obtained from ATCC and maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% FBS in a humidified 5.0% CO 2 atmosphere at 37.2°C with media changes every 48 hrs.
Tissue array: Human pancreatic cancer tissue arrays were obtained from US Biomax, Inc.
(Rockville, MD). The tissue arrays consisted of pancreatic cancer and normal tissues with stage and grade information of 101 cases, consisting of 208 cores (PA2082-024 and -025). H&E stained core images are available from the manufacturer at http://www.biomax.us/tissuearrays/Pancreas/PA2082. Tissue arrays were processed for immuno-histochemistry as per standard protocol. Briefly, slides were deparaffinized and endogenous peroxidases activity was blocked at room temperature by 5-10 min incubation in 0.3% H 2 O 2 in PBS (pH 7.7). The slides were then rinsed in PBS for 5 min followed by antigen retrieval by heating to about 95°C in citrate buffer (0.01M sodium citrate buffer, pH 6.0) for 10 min. The tissues were blocked using normal goat serum for 20 min at room temperature and followed by addition of primary antibody Page 6 of 32 (anti-uPA or anti-uPAR) for 60 min at room temperature. The slides were then rinsed in PBS followed by the addition of a HRP-conjugated secondary antibody for 20 min at room temperature. HRP substrate DAB (3,3´-diaminobenzidine tetrahydrochloride) at 1 mg/mL in 50 mM Tris, pH 7.2 and 0.3% H 2 O 2 was then added for the development of DAB substrate. Next, the slides were dehydrated and mounted with cover slips. Transmitted light images were obtained after hematoxylin staining, to determine uPAR and uPA expression levels.
Construction of shRNA expressing plasmid: shRNA expressing plasmids were constructed as described previously (18, 19) .
RT-PCR analysis:
MIA PaCa-2 and PANC-1 cells were transfected with pSV, puPA, puPAR, or pU2 for 72 hrs. The cells were collected and total cell RNA was isolated. Reverse transcriptase PCR was set up using primers specific for uPAR and uPA (Table 1 ). The PCR cycle was: 95°C-5', (95°C-30 sec, 65°C-1' 72°C-1') x 30, 72°C-10'. The PCR product was quantified and plotted relative to GAPDH expression as arbitrary units. 
Fibrin zymography:
The enzymatic activity and molecular weight of electrophoretically separated forms of uPA in the conditioned media of MIA PaCa-2 and PANC-1 cells transfected with pSV, puPA, puPAR, or pU2 were determined by SDS-PAGE as described previously (20, 21) . As stated, the acrylamide gels were enriched with purified plasminogen and fibrinogen before polymerization. Equal amounts of sample proteins were electrophoresed, and the gels were washed and stained to determine enzymatic activity as per standard protocols.
In vitro angiogenic assay: MIA PaCa-2 and PANC-1 cells (2×10 6 /well) were seeded and transfected with pSV, puPAR, puPA, or pU2. After a 24-hr incubation period, the conditioned In vivo angiogenic assay: The implantation technique of the dorsal skin-fold chamber model has been described previously (22) . Sterile small animal surgical techniques were followed.
Diffusion chambers were filled with 2×10 6 MIA PaCa-2 and PANC-1 cells, which were transfected with pSV, puPAR, puPA, or pU2 and suspended in 100-150 μL of sterile PBS. Mice were anesthetized using isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane)-saturated oxygen gas. Once the animal was anesthetized completely, a dorsal air sac was made in the mouse by injecting 10 mL of air. A 1.5-2 cm superficial incision was made horizontally along the edge of the dorsal air sac, and the air sac was opened. With the help of forceps, the chambers were placed underneath the skin and sutured carefully. After 10 days, the animals were anesthetized with ketamine/xylazine and sacrificed by intracardiac perfusion with saline (10 mL)
followed by a 10 mL of 10% formalin in 0.1 M standard phosphate buffer. The animals were carefully skinned around the implanted chambers and the implanted chambers were removed from the air sac fascia. The skin-fold covering the chambers was photographed under visible light. The number of blood vessels within the chamber in the area of the air sac fascia was counted and their lengths measured. MIA PaCa-2 and PANC-1 cells (2×10 6 /well) were seeded and transfected with pU2. After a 24-hr incubation period, the conditioned medium was removed and membranes were incubated with conditioned media. Following incubation, the membranes were washed and 1 mL of diluted biotin-conjugated antibody mix was added to the membranes and incubated at room temperature for 1-2 hours, followed by washing and addition of diluted HRP-conjugated streptavidin.
Angiogenesis antibody array:
Detection was based on ECL-protocols where membranes were exposed to X-ray films to visualize binding of angiogenic factors to membranes, which are seen as spots of varying intensities. Positive controls were used to normalize the results from different membranes being compared. Spot intensities were quantified using Image J software, and angiogenic molecules showing significant change in expression levels were identified. 
Matrigel invasion assay:

Orthotopic tumor model
Subcutaneous tumor growth:
We carried out subcutaneous implantation as previously described (24) . Briefly, MIA-PaCa-2 cells were harvested by trypsinization and washed with PBS. Cells were injected subcutaneously into mice in a total volume of 0.2 mL within 30 min of harvesting.
The subcutaneous tumors were used as the source of tissue for orthotopic implantation of tissue onto the pancreas.
Surgical orthotopic implantation of MIA-PaCa-2 tumors:
The following procedure was performed as described by Katz et al. (25) . MIA-PaCa-2 tumors in the exponential growth phase, grown subcutaneously in nude mice, were resected aseptically. Necrotic tissues were cut away, and the remaining healthy tumor tissues were cut with scissors and minced into 1 mm 3 pieces in Dulbecco's Modified Eagle's Medium (DMEM). Mice were then anesthetized using isoflurane (2-chloro-2-(difluoromethoxy)-1, 1, 1-trifluoro-ethane)-saturated oxygen gas, and their abdomens were sterilized with alcohol. An incision was created through the left upper abdominal pararectal line and peritoneum. The pancreas was carefully exposed, and 2 tumor pieces were transplanted onto the middle of the gland using a single surgical suture. The pancreas was then returned into the peritoneal cavity, and the abdominal wall and the skin were closed in 2 layers using 6-0 surgical suture. Three days after implantation, mice were given ip injections of pU2 five times at 150μg/mouse every other day. Thirty days after implantation, mice were sacrificed and pancreatic tissues were isolated and processed for paraffin embedding. Immunohistochemical analysis: Pancreatic tissues with tumors of control (untreated), pSV -and pU2-treated mice implanted with MIA PaCa-2 tumors were fixed in formaldehyde and embedded in paraffin as per standard protocols. Sections were deparaffinized as per standard protocol, pretreated with 0.3% H 2 O 2 to inactivate native peroxidases followed by incubation in 1% BSA in PBS for 1 hr, and subsequently transferred to primary antibody (uPAR, uPA or Lhx-2) diluted in 1% BSA in PBS (1:500). Sections were allowed to incubate in the primary antibody solution for 2 hrs at room temperature in a humidified chamber, followed by washes (3 at 10 min each) in 1% BSA in PBS and placed in a solution with the appropriate HRP-conjugated secondary antibody. The sections were allowed to incubate with the secondary antibody for 1 hr followed by washes in PBS (5 for 5 min each). HRP substrate DAB (3,3´-diaminobenzidine tetrahydrochloride) at 1 mg/mL in 50 mM Tris (pH 7.2) and 0.3% H 2 O 2 was then added for the development of DAB substrate. Transmitted light images were obtained after hematoxylin staining as per standard protocol to visualize the morphology of the sections. A control study was performed using a normal rabbit immunoglobulin fraction as the primary antibody (control Ab) instead of uPAR, uPA or Lhx-2.
In situ terminal-deoxy-transferase mediated dUTP nick end labeling (TUNEL) assay: A TUNEL apoptosis detection kit (Upstate Biotechnology Inc, Lake Placid, NY) was used for DNA fragmentation fluorescence staining and carried out according to the manufacturer's protocol. Briefly, MIA PaCa-2 tumor sections from control, pSV -and pU2-treated mice were incubated with a reaction mix containing biotin-dUTP and terminal deoxynucleotidyl transferase for 60 min. Fluorescein-conjugated avidin was applied to the sample, which was then incubated Immunofluorescence: MIA PaCa-2 and PANC-1 cells grown on chamber slides were transfected with pSV, puPAR, puPA or pU2. After 72 hrs, cells were fixed with 3.7% formaldehyde and incubated with 1% BSA in PBS at room temperature for 1 hr for blocking.
Then, the slides were washed with PBS and incubated with IgG anti-uPA (rabbit) and IgG antiLhx-2 (mouse) at a concentration of 1:200. The slides were incubated at room temperature for 4 hrs and washed three times with PBS to remove excess primary antibody. Cells were then incubated with anti-rabbit FITC conjugated IgG (1:500 dilution) and anti-mouse Texas-Red conjugated IgG (1:500 dilution). Next, the slides were washed three times, covered with glass cover slips using a DAPI containing mounting media and fluorescent photomicrographs were obtained using a triple filter cube (RGB).
Transcription factor binding array analysis: Transcription Factor (TF) protein-protein binding array was done using the TF Protein Array kit from Panomics (Catalog #MA3501-08, Redwood City, CA) as per the manufacturer's instructions. Briefly, recombinant human uPA (huPA) protein (American Diagnostics) was suspended in 1X blocking buffer at a concentration of 100 ng/mL. The TF membranes were incubated in 1X blocking buffer for 2 hrs at room temperature (RT) followed by incubation with huPA in 1X blocking buffer for 2 hrs at RT. This was followed by washings and further incubation with anti-uPA antibody followed by secondary HRPconjugated antibody as per kit instructions. Detection for HRP was done using the provided detection buffers followed by exposure of membranes to x-ray film. Binding of huPA to TFs was observed as spots on the x-ray film. 
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Statistical analysis: All experiments were repeated in triplicate with the exception of the human pancreatic tissue array. A p value of 0.01 or less was considered significant.
RESULTS
Human pancreatic carcinoma and adenocarcinoma show increased expression of uPAR and uPA
We analyzed human pancreatic tissue arrays to determine expression levels of both uPAR and uPA by immunohistochemistry. Identical tissue arrays obtained by serial sectioning were used for this study. We observed that, expression of both uPAR and uPA was co-localized in most cases (Fig. 1A) . uPA expression was seen uniformly throughout the tumor tissue with little expression in the large excretory ducts, whereas uPAR expression was observed in the tumor tissues as well as in the excretory ducts (Figs. 1B-C) . In most tissues, overexpression of uPA was 
Page 14 of 32 levels of uPA in puPA-and pU2-transfected cells as compared to pSV-transfected and control cells ( Fig. 2A) . From the fibrin zymography results, we observed a decrease in uPA activity in puPA and pU2-transfected cells as compared to pSV-transfected and control cells by more than two and four fold in both cell lines respectively (Fig. 2B&2C) . uPAR protein expression decreased by 3-fold in puPAR-transfected cells and 4-fold in pU2-transfected cells as compared to the controls (Figs. 2B-D) . Cells transfected with puPA had decreased uPA activity but no significant change in uPAR expression levels (Fig. 2B-D) . 57±2% and PANC-1: 58±3%) was found to be more than 50% (Fig. 3B) . We next sought to determine whether the accumulation of cells in the sub-G 0/1 phase was indicative of apoptosis. and rudimentary network formation in endothelial cells grown in conditioned media from pU2-transfected MIA PaCa-2 or PANC-1 cells (Fig. 4A) . Quantitative analysis indicated that transfection with puPAR (MIA PaCa-2 37±3% and PANC-1: 55±4%) or puPA (MIA PaCa-2: 36±2% and PANC-1: 41±2%) decreased capillary network formation (controls considered as 100% angiogenic). Transfection with pU2 (MIA PaCa-2: 68±2% and PANC-1: 78±4%) caused the most significant decrease in endothelial cell network formation (Fig. 4A ).
To further demonstrate the effect of uPAR and uPA downregulation on tumor angiogenesis, we used the dorsal skin-fold chamber assay in vivo model system. Implantation of a chamber containing MIA PaCa-2 or PANC-1 cells pre-transfected with pSV, puPAR, puPA or pU2 resulted in the development of microvessels with curved thin structures. MIA PaCa-2 or PANC-1 cells transfected with pU2 showed in no new development of vasculature, whereas puPAR-and puPA-transfected cells did result in formation of neovasculature but was less than that of control or pSV-transfected cells where maximum neovasculature formation was observed (Fig. 4B ).
Quantitative analysis of neovasculature from the in vivo angiogenesis assay indicated that controls and pSV-treated cells had similar increases in vasculature, whereas puPAR-treated cells (MIA PaCa-2: 28±6% and PANC-1: 36±3%) and puPA-treated cells (MIA PaCa-2: 37±3% and PANC-1: 15±3%) had decreased angiogenesis. pU2-treated cells (MIA PaCa-2: 88±3% and PANC-1: 85±3%) exhibited little increase in vasculature (Fig. 4B) .
Simultaneous downregulation of uPAR and uPA in MIA PaCa-2 and PANC-1 cells regulates expression of angiogenic factors
To further analyze the effect of pU2 on angiogenic inhibition, we used an antibody array specific for angiogenic factors. We used conditioned media from untransfected and pU2-transfected MIA To determine the in vivo effect of pU2 on pancreatic cancer cells, we used an orthotopic tumor model. Untreated mice pancreas showed normal pancreatic morphology with well-defined acini and islets of langerhans. In the control and pSV-treated mice, pancreatic tissues were infiltrated with tumor cells. However, in pU2-treated mice, we observed necrotic tumor tissue and decreased tumor cell density when compared to controls. Immunohistochemical analysis for uPAR and uPA expression indicated that normal pancreatic tissue expressed little to no uPAR or uPA, whereas mice with orthotopic pancreatic tumors (control and pSV-treated) showed strong expression of both uPAR and uPA (expression was stronger at the invasive fronts) ( Figure 5A ).
Mice treated with pU2 showed very low expression levels of both uPAR and uPA ( Figure 5A ).
In situ TUNEL assay showed that pU2-treated orthotopic tumors showed presence of DNA damage (green fluorescence) (Fig. 5A) . Determination of percent TUNEL expression indicated that 63±9% cells in pU2-treated tumors had DNA damage whereas no DNA damage was observed in control or pSV-treated mice. We measured tumor volumes by serial sectioning, and we observed that control (550±50 mm 3 ) and pSV-treated (620±100 mm 3 and PANC-1 cells revealed that uPA was present in the cytoplasm, cell membrane and the nucleus with uPA and Lhx-2 co-localized in the nucleus and cytoplasm (Fig. 6A ).
Immunohistochemical analysis of Lhx-2 in pancreatic tumor tissues revealed that Lhx-2 is strongly expressed at the invasive front of tumors surrounding the acinar tissues (Fig. 6B) . To determine the role of uPA in the nucleus, we performed a transcription factor binding assay using a protein array of known transcription factors. The results demonstrate that uPA is bound to the transcription factor Lhx-2 (Fig. 6C) . We performed western blot analysis of nuclear extracts of MIA PaCa-2 and PANC-1 cells transfected with pSV, puPAR, puPA or pU2 for uPA and Lhx-2 expression. In MIA PaCa-2 cells, transfection with puPAR, puPA or pU2 caused a decrease in nuclear localization of uPA with a corresponding decrease in the expression level of Lhx-2. In PANC-1 cells, transfection with puPAR, puPA or pU2 caused a decrease in nuclear uPA similar to MIA PaCa-2 cells but did not result a decrease in the levels of nuclear Lhx-2 (Fig. 6D ). We present a rudimentary theoretical model for the possible role of uPA and Lhx-2 in maintenance of an invasive phenotype and the possible role of Lhx-2 in initiating differentiation (Fig. 6D) . 
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DISCUSSION
In the present study, we have attempted to retard the invasive ability and angiogenic potential of pancreatic cancer cells both in vitro and in vivo. From the human tissue array analysis, we observed that both uPAR and uPA were highly expressed in human pancreatic cancer tissues, and the expression of uPAR was always correlated with the expression of its ligand uPA. Researchers have demonstrated that activation of the uPAR-uPA system is an early event in the development of pancreatic ductal adenocarcinoma and that uPAR gene amplifications identify a subgroup of particularly aggressive tumors, thereby making the uPARuPA system a critical and highly promising target for therapeutic interventions (10) .
To target the uPAR-uPA system, we used plasmids expressing shRNA targeting uPAR and uPA (19, (26) (27) (28) (29) (30) . Using plasmid-mediated RNAi induction did not cause non-specific inhibition, which indicates that no off-target effects were present. From the Matrigel invasion assay, we observed that the simultaneous downregulation of uPAR and uPA caused a significant decrease in invasive potential as compared to cells downregulated for either uPAR or uPA.
Recent research using papillary thyroid carcinoma (PTC) cells provide new functional evidence of the uPAR-uPA system's role in PTC invasion/metastasis (31) . Researchers have also demonstrated that inhibiting the activity of the uPAR and associated molecules like integrins (32) causes a significant decrease of migration and intracellular signaling in cancer cells. The uPAR-uPA system is known to be localized at the invasive front of tumor cells, activating plasmin to plasminogen and further enabling the activation of various proteases (33) .
Interestingly, the downregulation of the uPAR-uPA system also caused the activation of pro- 
Page 20 of 32 simultaneously downregulated for uPAR and uPA had strong CAD activation, indicating that both uPAR and uPA are necessary for maintenance of a viable invasive phenotype.
The classical role of the uPAR-uPA system is the activation of plasmin, and plasminoverproducing cancer cells are known to also overexpress tPA, uPA and uPAR. Plasmin is also known to promote angiogenesis and metastasis (34) . The mechanisms by which plasmin promotes angiogenesis and metastasis remain poorly understood. We hypothesize that suppressing the plasmin activating system could essentially inhibit angiogenic activation. Our and transfected cells were subjected to RT-PCR using primers specific for uPAR and uPA.
GAPDH primers were used to verify that equal amounts of total RNA were used during cDNA synthesis (A). The amplified (RT-PCR) fragments were quantified by densitometry analysis (A). Standard H&E staining was also done to determine tumor and pancreatic morphology (A). 
